A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs SEA CD40 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Solid tumours
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 12 Mar 2018 Planned number of patients changed from 290 to 350.
- 12 Mar 2018 Planned End Date changed from 1 Jul 2021 to 1 Sep 2022.
- 12 Mar 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Jun 2021.